(0.34%) 5 035.63 points
(0.42%) 38 062 points
(0.55%) 15 692 points
(0.05%) $79.04
(3.93%) $2.01
(-0.55%) $2 298.40
(0.24%) $26.81
(0.45%) $959.20
(0.30%) $0.936
(0.40%) $11.07
(0.30%) $0.801
(-1.27%) $92.07
Live Chart Being Loaded With Signals
WIN-Partners Co., Ltd., through its subsidiaries, distributes medical devices to medical institutions primarily in Japan. The company offers percutaneous transluminal coronary angioplasty balloon catheters, drug-eluting stents, and intravascular ultrasound catheters; pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators, and ablation catheters; and stent grafts, transcatheter heart valves, and mechanical heart valves...
Stats | |
---|---|
Šios dienos apimtis | 13 100.00 |
Vidutinė apimtis | 49 928.00 |
Rinkos kapitalizacija | 33.31B |
EPS | ¥0 ( 2024-02-06 ) |
Kita pelno data | ( ¥0 ) 2024-05-09 |
Last Dividend | ¥14.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 19.61 |
ATR14 | ¥0.906 (0.08%) |
Tūris Koreliacija
WIN-Partners Co., Ltd. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
WIN-Partners Co., Ltd. Koreliacija - Valiuta/Žaliavos
WIN-Partners Co., Ltd. Finansinės ataskaitos
Annual | 2022 |
Pajamos: | ¥70.85B |
Bruto pelnas: | ¥8.66B (12.23 %) |
EPS: | ¥72.04 |
FY | 2022 |
Pajamos: | ¥70.85B |
Bruto pelnas: | ¥8.66B (12.23 %) |
EPS: | ¥72.04 |
FY | 2022 |
Pajamos: | ¥66.39B |
Bruto pelnas: | ¥8.52B (12.83 %) |
EPS: | ¥63.88 |
FY | 2021 |
Pajamos: | ¥62.12B |
Bruto pelnas: | ¥7.74B (12.47 %) |
EPS: | ¥53.66 |
Financial Reports:
No articles found.
WIN-Partners Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥0 (N/A) |
¥14.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥12.50 | 2011-03-29 |
Last Dividend | ¥14.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 14 | -- |
Total Paid Out | ¥255.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.11 | -- |
Div. Sustainability Score | 5.79 | |
Div.Growth Potential Score | 4.00 | |
Div. Directional Score | 4.89 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8369.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7762.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6937.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
6294.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
5018.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
4220.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3434.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2540.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
9468.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8097.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0228 | 1.500 | 9.54 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0381 | 1.200 | 8.73 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0758 | 1.500 | -0.268 | -0.403 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.905 | 0.800 | 5.48 | 4.38 | [1 - 3] |
quickRatioTTM | 1.697 | 0.800 | 4.72 | 3.78 | [0.8 - 2.5] |
cashRatioTTM | 0.825 | 1.500 | 6.53 | 9.79 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 196 918 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 13.65 | 2.00 | 5.45 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 13.65 | 2.00 | 3.17 | 6.35 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.123 | 1.000 | -1.278 | -1.278 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0318 | 1.000 | -1.365 | -1.365 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 1.674 | 0.800 | 2.17 | 1.737 | [0.5 - 2] |
Total Score | 5.79 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 19.61 | 1.000 | 8.12 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0758 | 2.50 | -0.173 | -0.403 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 13.65 | 2.00 | 5.45 | 6.35 | [0 - 30] |
dividendYielPercentageTTM | 4.30 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 13.65 | 2.00 | 5.45 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 1.535 | 1.500 | 3.10 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.00524 | 1.000 | -2.37 | 0 | [0.1 - 0.5] |
Total Score | 4.00 |
WIN-Partners Co., Ltd.
WIN-Partners Co., Ltd., through its subsidiaries, distributes medical devices to medical institutions primarily in Japan. The company offers percutaneous transluminal coronary angioplasty balloon catheters, drug-eluting stents, and intravascular ultrasound catheters; pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators, and ablation catheters; and stent grafts, transcatheter heart valves, and mechanical heart valves. It also provides peripheral vascular stents, carotid artery stents, and embolic coils; and insulin pumps, as well as continuous glucose monitoring and magnetic resonance imaging equipment. The company was founded in 1973 and is headquartered in Tokyo, Japan.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.